Li HY, Jing YM, Shen X, Tang MY, Shen HH, Li XW, Wang ZS, Su F. Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(9): 3913-3931 [PMID: 39350977 DOI: 10.4251/wjgo.v16.i9.3913]
Corresponding Author of This Article
Fang Su, Doctor, MD, PhD, Academic Research, Researcher, Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287 Changhuai Road, Longzihu District, Bengbu 233000, Anhui Province, China. sufang2899@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Clinical and Translational Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Hui-Yuan Li, Xue Shen, Ming-Yue Tang, Hong-Hong Shen, Xin-Wei Li, Zi-Shu Wang, Fang Su, Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu 233000, Anhui Province, China
Yi-Ming Jing, Department of Neurology, The First Affiliated Hospital of Bengbu Medical University, Bengbu 233000, Anhui Province, China
Author contributions: Li HY, Jing YM, Tang MY, and Su F designed and wrote the manuscript; Li HY completed the experiments; Li HY, Jing YM, Shen HH, and Li XW analyzed the data; Li HY, Jing YM, Shen X, Li XW, and Wang ZS were responsible for the literature search to improve the work and revise the manuscript. All authors reviewed the manuscript and approved its publication.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fang Su, Doctor, MD, PhD, Academic Research, Researcher, Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287 Changhuai Road, Longzihu District, Bengbu 233000, Anhui Province, China. sufang2899@163.com
Received: March 28, 2024 Revised: June 3, 2024 Accepted: July 8, 2024 Published online: September 15, 2024 Processing time: 164 Days and 21.6 Hours
Core Tip
Core Tip: Our results of immunohistochemical staining, quantitative real-time polymerase chain reaction, and immunoblotting in combination with those obtained from The Cancer Genome Atlas database showed that protein tyrosine phosphatase non-receptor 2 (PTPN2) was highly expressed in patients with hepatocellular carcinoma (HCC) and was associated with a poor prognosis. Kyoto Encyclopedia of Genes and Genomes enrichment analysis showed that PTPN2 was associated with multiple pathways, including cancer-related pathway, the Notch signaling pathway, and the MAPK signaling pathway. Analysis by constructing a risk model based on PTPN2 revealed that immune escape was significantly enhanced in the high-risk group compared with the low-risk group. In this study, PTPN2 was investigated from multiple biological perspectives, and was found to have the potential to serve as a biomarker of poor prognosis in HCC and to mediate immune escape.
